Как победить диабет. Руководство по питанию и образу жизни

8. Shiwaku K, Anuurad E, Enkhmaa B, et al. Overweight Japanese with body mass indexes of 23.0–24.9 have higher risks for obesity-associated disorders: a comparison of Japanese and Mongolians. Int J Obes Relat Metab Disord. 2004; 28(1): 152–158.

9. Gray LJ, Yates T, Davies MJ, et al. Defining obesity cut-off points for migrant South Asians. PLoS One. 2011; 6(10): 4–10.

10. Nishida C. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363(9403): 157–163.

11. Center for Health Statistics N. Table 53. Selected health conditions and risk factors, by age: United States, selected years 1988–1994 through 2015–2016; 2017. URL: https://www.cdc.gov/ nchs/hus/contents2017.htm#053. Accessed January 21, 2019.

12. Corsica JA, Pelchat ML. Food addiction: true or false? Curr Opin Gastroenterol. 2010; 26(2): 165–169.

13. Ifland JR, Preuss HG, Marcus MT, et al. Refined food addiction: a classic substance use disorder. Med Hypotheses. 2009; 72(5): 518–526.

14. Liu Y, von Deneen KM, Kobeissy FH, Gold MS. Food addiction and obesity: Evidence from bench to bedside. J Psychoactive Drugs. 2010; 42(2): 133–145.

15. Holtcamp W. Obesogens: An environmental link to obesity. Environ Health Perspect. 2012; 120(2): a62–68.

16. Grün F, Blumberg B. Minireview: The case for obesogens. Mol Endocrinol. 2009; 23(8): 1127–1134.

17. Janesick A, Blumberg B. Endocrine disrupting chemicals and the developmental programming of adipogenesis and obesity. Birth Defects Res C Embryo Today. 2011; 93(1): 34–50.

18. Darbre PD. Endocrine Disruptors and Obesity. Curr Obes Rep. 2017; 6(1): 18–27.

19. Chao A, Grey M, Whittemore R, et al. Examining the mediating roles of binge eating and emotional eating in the relationships between stress and metabolic abnormalities. J Behav Med. 2016; 39(2): 320–332.

20. Guerdjikova AI, Mori N, Casuto LS, McElroy SL. Binge Eating Disorder. Psychiatr Clin North Am. 2017; 40(2): 255–266.

21. Lim EL, Hollingsworth KG, Aribisala BS, et al. Reversal of type 2 diabetes: Normalization of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011; 54(10): 2506–2514.

22. Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): An open-label, cluster-randomised trial. Lancet. 2017; 391(10120): 541–551.

23. Bhatt AA, Choudhari PK, Mahajan RR, et al. Effect of a low-calorie diet on restoration of normoglycemia in obese subjects with type 2 diabetes. Indian J Endocrinol Metab. 2017; 21(5): 776–780.

24. Cheng C-W, Villani V, Buono R, et al. Fasting-mimicking diet promotes Ngn3-driven b-Cell regeneration to reverse diabetes. Cell. 2017; 168(5): 775–788.e12.

25. Patterson RE, Sears DD. Metabolic effects of intermittent fasting. Annu Rev Nutr. 2017; 37(1): 371–393.

26. Jane L, Atkinson G, Jaime V, et al. Intermittent fasting interventions for the treatment of overweight and obesity in adults aged 18 years and over: a systematic review protocol. JBI Database Syst Rev Implement Reports. 2015; 13(10): 60–68.

27. Rothschild J, Hoddy KK, Jambazian P, Varady KA. Time-restricted feeding and risk of metabolic disease: a review of human and animal studies. Nutr Rev. 2014; 72(5): 308–318.

28. Longo VD, Panda S. Fasting, circadian rhythms, and time-restricted feeding in healthy lifespan. Cell Metab. 2016; 23(6): 1048–1059.

29. Mattson MP, Longo VD, Harvie M. Impact of intermittent fasting on health and disease processes. Ageing Res Rev. 2017; 39: 46–58.

30. Harvie M, Howell A. Potential benefits and harms of intermittent energy restriction and intermittent fasting amongst obese, overweight and normal weight subjects – A narrative review of human and animal evidence. Behav Sci (Basel). 2017; 7(4): 4.

31. Brandhorst S, Choi IY, Wei M, et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan. Cell Metab. 2015; 22(1): 86–99.

32. Ouchi N, Higuchi A, Ohashi K, et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science (80-). 2010; 329(5990): 454–457.

33. Karczewski J, Śledzińska E, Baturo A, et al. Obesity and inflammation. Eur Cytokine Netw. 2018; 29(3): 83–94.

34. Sato J, Kanazawa A, Watada H. Type 2 diabetes and Bacteremia. Ann Nutr Metab. 2017; 71(1): 17–22.

35. Teixeira TFS, Collado MC, Ferreira CLLF, Bressan J, Peluzio M do CG. Potential mechanisms for the emerging link between obesity and increased intestinal permeability. Nutr Res. 2012; 32(9): 637–647.